Bill Amendment: IL SB1607 | 2017-2018 | 100th General Assembly

NOTE: For additional amemendments please see the Bill Drafting List

---

Bill Title: CONTROLLED SUBSTANCES MONITOR

Status: 2018-01-08 - Public Act . . . . . . . . . 100-0575 [SB1607 Detail]

Download: Illinois-2017-SB1607-Senate_Amendment_001.html

---

Sen. Melinda Bush

Filed: 3/7/2017

10000SB1607sam001 LRB100 11093 RLC 23050 a
AMENDMENT TO SENATE BILL 1607
AMENDMENT NO. ______. Amend Senate Bill 1607 by replacing
everything after the enacting clause with the following:
"Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 314.5 and 316 as follows:
(720 ILCS 570/314.5)
Sec. 314.5. Medication shopping; pharmacy shopping.
(a) It shall be unlawful for any person knowingly or
intentionally to fraudulently obtain or fraudulently seek to
obtain any controlled substance or prescription for a
controlled substance from a prescriber or dispenser while being
supplied with any controlled substance or prescription for a
controlled substance by another prescriber or dispenser,
without disclosing the fact of the existing controlled
substance or prescription for a controlled substance to the
prescriber or dispenser from whom the subsequent controlled

10000SB1607sam001 - 2 - LRB100 11093 RLC 23050 a
substance or prescription for a controlled substance is sought.
(a-5) Before issuing a prescription for a Schedule II, III,
IV, or V controlled substance, a prescriber or his or her
designee shall access the prescription monitoring program to
determine compliance with this Section.
(b) It shall be unlawful for a person knowingly or
intentionally to fraudulently obtain or fraudulently seek to
obtain any controlled substance from a pharmacy while being
supplied with any controlled substance by another pharmacy,
without disclosing the fact of the existing controlled
substance to the pharmacy from which the subsequent controlled
substance is sought.
(c) A person may be in violation of Section 3.23 of the
Illinois Food, Drug and Cosmetic Act or Section 406 of this Act
when medication shopping or pharmacy shopping, or both.
(d) When a person has been identified as having 3 or more
prescribers or 3 or more pharmacies, or both, that do not
utilize a common electronic file as specified in Section 20 of
the Pharmacy Practice Act for controlled substances within the
course of a continuous 30-day period, the Prescription
Monitoring Program shall may issue an unsolicited report to the
prescribers, dispensers, and their designees informing them of
the potential medication shopping. A prescriber who receives
the report, either personally or through an agent at his or her
place of practice, shall be prohibited from issuing a
controlled substance to that same person unless the prescriber

10000SB1607sam001 - 3 - LRB100 11093 RLC 23050 a
signs a statement on the prescription acknowledging receipt of
the report. If a pharmacy or pharmacist receives a prescription
for a person he or she knows or should know to be the subject of
the report, and the prescriber fails to provide the required
acknowledgement, the pharmacy or pharmacist must contact the
prescriber and obtain a signature on the acknowledgement before
filling the prescription.
(e) Nothing in this Section shall be construed to create a
requirement that any prescriber, dispenser, or pharmacist
request any patient medication disclosure, report any patient
activity, or prescribe or refuse to prescribe or dispense any
medications.
(f) This Section shall not be construed to apply to
inpatients or residents at hospitals or other institutions or
to institutional pharmacies.
(g) Any patient feedback, including grades, ratings, or
written or verbal statements, in opposition to a clinical
decision that the prescription of a controlled substance is not
medically necessary shall not be the basis of any adverse
action, evaluation, or any other type of negative
credentialing, contracting, licensure, or employment action
taken against a prescriber or dispenser.
(Source: P.A. 99-480, eff. 9-9-15.)
(720 ILCS 570/316)
Sec. 316. Prescription monitoring program.

10000SB1607sam001 - 4 - LRB100 11093 RLC 23050 a
(a) The Department must provide for a prescription
monitoring program for Schedule II, III, IV, and V controlled
substances that includes the following components and
requirements:
(1) The dispenser must transmit to the central
repository, in a form and manner specified by the
Department, the following information:
(A) The recipient's name and address.
(B) The recipient's date of birth and gender.
(C) The national drug code number of the controlled
substance dispensed.
(D) The date the controlled substance is
dispensed.
(E) The quantity of the controlled substance
dispensed and days supply.
(F) The dispenser's United States Drug Enforcement
Administration registration number.
(G) The prescriber's United States Drug
Enforcement Administration registration number.
(H) The dates the controlled substance
prescription is filled.
(I) The payment type used to purchase the
controlled substance (i.e. Medicaid, cash, third party
insurance).
(J) The patient location code (i.e. home, nursing
home, outpatient, etc.) for the controlled substances

10000SB1607sam001 - 5 - LRB100 11093 RLC 23050 a
other than those filled at a retail pharmacy.
(K) Any additional information that may be
required by the department by administrative rule,
including but not limited to information required for
compliance with the criteria for electronic reporting
of the American Society for Automation and Pharmacy or
its successor.
(2) The information required to be transmitted under
this Section must be transmitted not later than the end of
the next business day after the date on which a controlled
substance is dispensed, or at such other time as may be
required by the Department by administrative rule.
(3) A dispenser must transmit the information required
under this Section by:
(A) an electronic device compatible with the
receiving device of the central repository;
(B) a computer diskette;
(C) a magnetic tape; or
(D) a pharmacy universal claim form or Pharmacy
Inventory Control form;
(4) The Department may impose a civil fine of up to
$100 per day for willful failure to report controlled
substance dispensing to the Prescription Monitoring
Program. The fine shall be calculated on no more than the
number of days from the time the report was required to be
made until the time the problem was resolved, and shall be

10000SB1607sam001 - 6 - LRB100 11093 RLC 23050 a
payable to the Prescription Monitoring Program.
(b) The Department, by rule, may include in the monitoring
program certain other select drugs that are not included in
Schedule II, III, IV, or V. The prescription monitoring program
does not apply to controlled substance prescriptions as
exempted under Section 313.
(c) The collection of data on select drugs and scheduled
substances by the Prescription Monitoring Program may be used
as a tool for addressing oversight requirements of long-term
care institutions as set forth by Public Act 96-1372. Long-term
care pharmacies shall transmit patient medication profiles to
the Prescription Monitoring Program monthly or more frequently
as established by administrative rule.
(d) The Department of Human Services shall appoint a
full-time Clinical Director of the Prescription Monitoring
Program.
(e) (Blank). Within one year of the effective date of this
amendatory Act of the 99th General Assembly, the Department
shall adopt rules establishing pilot initiatives involving a
cross-section of hospitals in this State to increase electronic
integration of a hospital's electronic health record with the
Prescription Monitoring Program on or before January 1, 2019 to
ensure all providers have timely access to relevant
prescription information during the treatment of their
patients. These rules shall also establish pilots that enhance
the electronic integration of outpatient pharmacy records with

10000SB1607sam001 - 7 - LRB100 11093 RLC 23050 a
the Prescription Monitoring Program to allow for faster
transmission of the information required under this Section. In
collaboration with the Department of Human Services, the
Prescription Monitoring Program Advisory Committee shall
identify funding sources to support the pilot projects in this
Section and distribution of funds shall be based on voluntary
and incentive-based models. The rules adopted by the Department
shall also ensure that the Department continues to monitor
updates in Electronic Health Record Technology and how other
states have integrated their prescription monitoring databases
with Electronic Health Records.
(f) Within one year of the effective date of this
amendatory Act of the 100th General Assembly, the Department
shall adopt rules requiring all Electronic Health Records
Systems to interface with the Prescription Monitoring Program
application program on or before January 1, 2021 to ensure that
all providers have access to specific patient records during
the treatment of their patients. These rules shall also address
the electronic integration of pharmacy records with the
Prescription Monitoring Program to allow for faster
transmission of the information required under this Section.
The Department shall establish actions to be taken if a
prescriber's Electronic Health Records System does not
effectively interface with the Prescription Monitoring Program
within the required timeline.
(g) The Department, in consultation with the Advisory

10000SB1607sam001 - 8 - LRB100 11093 RLC 23050 a
Committee, shall adopt rules allowing licensed prescribers or
pharmacists who have registered to access the Prescription
Monitoring Program to authorize a designee to consult the
Prescription Monitoring Program on their behalf. The rules
shall include reasonable parameters concerning a
practitioner's authority to authorize a designee, and the
eligibility of a person to be selected as a designee.
(Source: P.A. 99-480, eff. 9-9-15.)".